Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy

Background & Aims Adefovir (ADV) resistance mutations induce low-level cross-resistance to tenofovir in vitro . Our aim was to compare viral kinetics, nucleos(t)ide analog resistance mutations, and quasispecies (QS) evolution during therapy with tenofovir disoproxil fumarate (TDF) or emtricitabi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2013-10, Vol.59 (4), p.684-695
Main Authors: Lavocat, Fabien, Dény, Paul, Pichoud, Christian, Al Hawajri, Nasser, Kitrinos, Kathryn, Borroto-Esoda, Katyna, Zoulim, Fabien
Format: Article
Language:English
Subjects:
Adenine - administration & dosage
Adenine - analogs & derivatives
Adult
Antiviral Agents - administration & dosage
Antivirals
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
DNA, Viral - blood
DNA, Viral - genetics
Double-Blind Method
Drug resistance
Drug Resistance, Viral - genetics
Drug Therapy, Combination
Emtricitabine
Evolution, Molecular
Female
Gastroenterology and Hepatology
Genotype
Hepatitis B Surface Antigens - genetics
Hepatitis B virus
Hepatitis B virus - drug effects
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - virology
Humans
Kinetics
Lamivudine - administration & dosage
Male
Middle Aged
Mutation
Organophosphonates - administration & dosage
Phylogeny
Quasispecies
RNA-Directed DNA Polymerase - genetics
Tenofovir
Time Factors
Treatment Failure
Viral genome heterogeneity
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims Adefovir (ADV) resistance mutations induce low-level cross-resistance to tenofovir in vitro . Our aim was to compare viral kinetics, nucleos(t)ide analog resistance mutations, and quasispecies (QS) evolution during therapy with tenofovir disoproxil fumarate (TDF) or emtricitabine + TDF (FTC/TDF) in selected patients with incomplete ADV responses. Methods Patients with chronic hepatitis B and incomplete response to ADV were randomized in a double-blind trial of TDF vs. FTC/TDF. Extensive analysis of QS evolution was performed in 17 patients through 48 weeks of treatment. Results At week 24, 48% of patients (9/17) achieved HBV DNA undetectability (
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2013.05.038